United Overseas Bank's Second-Quarter Profit Rose Marginally
By Kimberley Kao
United Overseas Bank's second-quarter net profit grew marginally, driven by fee income growth and lower credit allowances.
Profit for the April-June period rose around 1.0% to 1.425 billion Singapore dollars, equivalent to US$1.07 billion, compared with the same period a year earlier while total income fell 2% to S$3.48 billion, the bank said Thursday.
Net interest income fell 1.5% to S$2.40 billion. However, income from fees rose 18% to S$618 million for the quarter, near an all-time high, driven by a strong rebound in loan-related and wealth management fees thanks to a pickup in lending activity and improved market sentiment, the bank said.
Credit card fees also saw a strong double-digit growth, it said.
Allowance for credit and other losses declined 36% on year to S$232.0 million in the quarter, UOB said.
UOB's chief executive Wee Ee Cheong said the bank's balance sheet was strong, but cautioned that "global growth continues to be weighed down by geopolitical tensions and higher interest rates."
"We have successfully integrated operations in Malaysia, Indonesia and Thailand, and the one-time costs will be reduced substantially as we move towards integration in Vietnam next year," Wee said.
Write to Kimberley Kao at kimberley.kao@wsj.com
(END) Dow Jones Newswires
July 31, 2024 21:24 ET (01:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk